NasdaqCM - Nasdaq Real Time Price USD

Sonoma Pharmaceuticals, Inc. (SNOA)

Compare
2.5800
-0.0700
(-2.64%)
At close: January 13 at 4:00:00 PM EST

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Ms. Amy M. Trombly CEO, President & Director 608.82k -- 1968
Mr. Jerome J. Dvonch Chief Financial Officer 268.79k -- 1968
Mr. Bruce Thornton Executive VP, COO & Corporate Secretary 540.94k -- 1964
Mr. John Dal Poggetto Controller 433.36k -- 1972

Sonoma Pharmaceuticals, Inc.

5445 Conestoga Court
Suite 150
Boulder, CO 80301
United States
800 759 9305 https://sonomapharma.com
Sector: 
Healthcare
Full Time Employees: 
10

Description

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis; and Pediacyn, an atopic dermatitis hydrogel. It also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for use in emergencies and on mucous membranes, cuts, abrasions, burns, and body surfaces; and Endocyn root canal irrigation solutions. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Corporate Governance

Sonoma Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

February 6, 2025 at 9:00 PM UTC - February 10, 2025 at 9:00 PM UTC

Sonoma Pharmaceuticals, Inc. Earnings Date

Recent Events

January 3, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

December 20, 2024 at 12:00 AM UTC

S-8: Offering Registrations

November 21, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 7, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

October 22, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 20, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 28, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 21, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 15, 2024 at 12:00 AM UTC

DEFA14A: Proxy Statements

August 8, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

Related Tickers